196 related articles for article (PubMed ID: 12243845)
1. Omapatrilat--the story of Overture and Octave.
Coats AJ
Int J Cardiol; 2002 Nov; 86(1):1-4. PubMed ID: 12243845
[TBL] [Abstract][Full Text] [Related]
2. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
[TBL] [Abstract][Full Text] [Related]
3. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
Kostis JB; Packer M; Black HR; Schmieder R; Henry D; Levy E
Am J Hypertens; 2004 Feb; 17(2):103-11. PubMed ID: 14751650
[TBL] [Abstract][Full Text] [Related]
4. Recent clinical trials with omapatrilat: new developments.
Zanchi A; Maillard M; Burnier M
Curr Hypertens Rep; 2003 Aug; 5(4):346-52. PubMed ID: 12844471
[TBL] [Abstract][Full Text] [Related]
5. Trial logistics, implementation, and conduct of the OCTAVE mega study in Germany. Prospective, randomised, double-blind study to compare the efficacy and tolerability of omapatrilat and enalapril.
Kothny W; Kaaden R; Ludwig P; Chase D; Krekler M
Arzneimittelforschung; 2004; 54(8):474-9. PubMed ID: 15460215
[TBL] [Abstract][Full Text] [Related]
6. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
[TBL] [Abstract][Full Text] [Related]
7. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
[TBL] [Abstract][Full Text] [Related]
8. Omapatrilat. Bristol-Myers Squibb.
Tabrizchi R
Curr Opin Investig Drugs; 2001 Oct; 2(10):1414-22. PubMed ID: 11890357
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats.
Kostova E; Jovanoska E; Zafirov D; Jakovski K; Maleska V; Slaninka-Miceska M
Bratisl Lek Listy; 2005; 106(12):407-11. PubMed ID: 16642666
[TBL] [Abstract][Full Text] [Related]
10. [Omapatrilat--new drug for patients with hypertension and heart failure].
Dzielska-Olczak M
Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
[TBL] [Abstract][Full Text] [Related]
11. Omapatrilat.
Armstrong PW; Lorell BH; Nissen S; Borer J
Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187916
[No Abstract] [Full Text] [Related]
12. Omapatrilat for the management of heart failure and hypertension.
Husereau DR
Issues Emerg Health Technol; 2001 Jun; (17):1-4. PubMed ID: 11776285
[TBL] [Abstract][Full Text] [Related]
13. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study.
Mitchell GF; Izzo JL; Lacourcière Y; Ouellet JP; Neutel J; Qian C; Kerwin LJ; Block AJ; Pfeffer MA
Circulation; 2002 Jun; 105(25):2955-61. PubMed ID: 12081987
[TBL] [Abstract][Full Text] [Related]
14. Omapatrilat may indeed not be much superior (OMINOUS).
Cheng TO
Int J Cardiol; 2003 Sep; 91(1):113. PubMed ID: 12957741
[No Abstract] [Full Text] [Related]
15. Vasopeptidase inhibitors in heart failure.
Dawson A; Struthers AD
J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):156-9. PubMed ID: 12563565
[TBL] [Abstract][Full Text] [Related]
16. Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat.
Pickering TG
J Clin Hypertens (Greenwich); 2002; 4(5):371-3. PubMed ID: 12368583
[No Abstract] [Full Text] [Related]
17. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
18. [Omapatrilat for treatment of heart failure].
Yamazaki T
Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381
[No Abstract] [Full Text] [Related]
19. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure.
Sheth T; Parker T; Block A; Hall C; Adam A; Pfeffer MA; Stewart DJ; Qian C; Rouleau JL;
Am J Cardiol; 2002 Sep; 90(5):496-500. PubMed ID: 12208409
[TBL] [Abstract][Full Text] [Related]
20. Vasopeptidase inhibitors.
Weber MA
Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
